If your email program has trouble displaying this email, view as a webpage. FDA Approves New Combination Drug for Sedation in Dogs Today the U.S. Food and Drug Administration approved Zenalpha (medetomidine and vatinoxan hydrochlorides injection) for use as a sedative and analgesic (i.e., pain reliever) to help keep dogs sedated and comfortable while undergoing exams or certain medical procedures. Medetomidine is a sedative with analgesic properties that has already been approved for use in dogs. Medetomidine can cause a decrease in an animal's heart rate and can increase the chance of arrythmias (irregular heartbeat), which can be significant in some dogs. This is the first approval of vatinoxan by the FDA. Vatinoxan reduces the negative cardiovascular effects of medetomidine by keeping the heart rate closer to the normal range, thereby improving cardiovascular function and improving the safety profile of medetomidine while the dog is sedated. You are subscribed to updates from FDA's Center for Veterinary Medicine.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA